Your browser doesn't support javascript.
loading
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi, Hareth; Våtsveen, Thea Kristin; Lund, Johan; Heeg, Bart M S; Preiss, Birgitte; Alici, Evren; Møller, Michael Boe; Wader, Karin Fahl; Møller, Hanne E H; Grøseth, Lill Anny; Østergaard, Brian; Dai, Hong Yan; Holmberg, Erik; Gahrton, Gösta; Waage, Anders; Abildgaard, Niels.
Afiliação
  • Nahi H; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Våtsveen TK; KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Lund J; Department of Pathology, St Olavs Hospital, Trondheim, Norway.
  • Heeg BM; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Preiss B; PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands.
  • Alici E; Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.
  • Møller MB; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Wader KF; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Møller HE; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Grøseth LA; KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Østergaard B; Department of Oncology, St Olavs Hospital, Trondheim, Norway.
  • Dai HY; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Holmberg E; KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Gahrton G; Department of Hematology, St Olavs Hospital, Trondheim, Norway.
  • Waage A; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Abildgaard N; Department of Pathology, St Olavs Hospital, Trondheim, Norway.
Eur J Haematol ; 96(1): 46-54, 2016 Jan.
Article em En | MEDLINE | ID: mdl-25779478
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 1 / Aberrações Cromossômicas / Inibidores de Proteassoma / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Suécia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 1 / Aberrações Cromossômicas / Inibidores de Proteassoma / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Suécia País de publicação: Reino Unido